[1]Malamut G., Matysiak-Budnik T., Grosdidier E. Adult celiac diseases with severe or partial villous atrophy: A comparative study. Gastroenterol Clin Biol. 2008;32:236-242.
[2]Malamut G., Murray J., Cellier C. Refractory Celiac disease. Gastrointest Endosc Clin N Am. 2012;22:759-772. 4
[3]Barret M., Malamut G., Rahmi G. Diagnostic yield of capsule endoscopy in refractory celiac disease. Am J Gastroenterol. 2012;107:1546-1553. 10
[4]Malamut G., Afchain P., Verkarre V. Presentation and long-term follow-up of refractory celiac disease: Comparison of type I with type II. Gastroenterology. 2009;136:81-90.
[5]Canova C., Pitter G., Zanier L., Zanotti R., Simonato L., Ludvigsson J.F. Inflammatory Bowel Diseases in children and young adults with celiac disease. A Multigroup Matched Comparison. Inflamm Bowel Dis. 2017;23:1996-2000. 11
[6]Mukewar S.S., Sharma A., Rubio-Tapia A., Wu T.T., Jabri B., Murray J.A. Open-capsule budesonide for refractory celiac disease. Am J Gastroenterol. 2017;112:959-967. 6
[7]Dray X., Joly F., Lavergne-Slove A., Treton X., Bouhnik Y., Messing B. A severe but reversible refractory sprue. Gut. 2006;55:1210-1211.
[8]Al-Toma A., Goerres M.S., Meijer J.W. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol. 2006;4:1322-1327.
[9]Al-Toma A., Visser O.J., van Roessel H.M. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood. 2007;109:2243-2249. 5
[10]Cellier C, Bouma G, van Gils T, et al. AMG 714 (anti-IL-15 Mab) halts the progression of aberrant intraepithelial lymphocytes in refractory celiac disease type II (RCDII): A phase 2A randomized, doubleblind, placebo-controlled study evaluating AMG714 in adult patients with RCDII/pre-EATL. DDW 2018.